These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29762046)

  • 21. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
    Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
    Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF
    PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Moe SM; Abdalla S; Chertow GM; Parfrey PS; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Dehmel B; Goodman WG; Drüeke TB;
    J Am Soc Nephrol; 2015 Jun; 26(6):1466-75. PubMed ID: 25505257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
    Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Liu Y; Yang Q; Chen G; Zhou T
    Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M; Shimazaki R; Akizawa T;
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.
    Briggs AH; Parfrey PS; Khan N; Tseng S; Dehmel B; Kubo Y; Chertow GM; Belozeroff V
    Med Decis Making; 2016 Nov; 36(8):965-72. PubMed ID: 26987347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
    Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
    Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.
    Evans M; Methven S; Gasparini A; Barany P; Birnie K; MacNeill S; May MT; Caskey FJ; Carrero JJ
    Sci Rep; 2018 Feb; 8(1):2103. PubMed ID: 29391567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cinacalcet and Clinical Outcomes in Dialysis.
    Komaba H; Fukagawa M
    Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis.
    Sun Y; Tian B; Sheng Z; Wan P; Xu T; Yao L
    BMC Nephrol; 2020 Jul; 21(1):316. PubMed ID: 32736534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical outcomes of parathyroidectomy for secondary hyperparathyroidism resistant to calcimimetic treatment: A retrospective single-center cohort study.
    Okada M; Tominaga Y; Ichimori T; Tomosugi T; Hiramitsu T; Tsuzuki T
    Ther Apher Dial; 2021 Apr; 25(2):188-196. PubMed ID: 32592622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.